Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03676647 · ClinicalTrials.gov registry record
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
A clinical trial of Thyroid Gland Nodule, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- 22
- Enrollment target
- 1
- Study location
NCT03676647: Recruiting study of Thyroid Gland Nodule, sponsored by City of Hope Medical Center.
NCT03676647 is a study of Thyroid Gland Nodule that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 22 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03676647, a study of Thyroid Gland Nodule, is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial studies how well the diagnostic deoxyribonucleic acid (DNA) methylation signature works in detecting thyroid cancer in patients with thyroid nodules. Using diagnostic testing, such as the diagnostic DNA methylation signature, may be a less invasive way to check for thyroid cancer.
Primary Outcome
Will be assessed by taking the ratio of the number of thyroid cancer specimens diagnosed as cancer using the DDMS and the total number of thyroid cancer specimens according to the final diagnosis. Will determine the 95% confidence intervals.
Conditions Studied
Interventions
- OTHER Diagnostic DNA Methylation Signature
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2026-04-25 |
| Est. Completion | 2028-09-25 |
What NCT03676647 shows while recruiting
NCT03676647 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 22 participants, a relatively small participant target.
The record links to 1 condition, with Thyroid Gland Nodule appearing as the primary indexed condition, and to 1 intervention - of which Diagnostic DNA Methylation Signature is the first listed.
NCT03676647 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03676647 about?
NCT03676647 is a clinical study titled "Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules". This trial studies how well the diagnostic deoxyribonucleic acid (DNA) methylation signature works in detecting thyroid cancer in patients with thyroid nodules. Using diagnostic testing, such as the diagnostic DNA methylation signature, may be a less invasive way to check for thyroid cancer.
What is the current status of trial NCT03676647?
This trial is currently recruiting. The enrollment target is 22 participants. The study started on 2026-04-25. Estimated completion is 2028-09-25.
What conditions does trial NCT03676647 study?
This clinical trial studies the following conditions: Thyroid Gland Nodule.
What interventions are being tested in trial NCT03676647?
The interventions under investigation include: Diagnostic DNA Methylation Signature (OTHER).
Who is sponsoring clinical trial NCT03676647?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03676647 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Gland Nodule
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
- NCT04640987 · 22 participants · Phase 1
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI